Determination of copper and other trace elements in serum samples from patients with biliary tract cancers: prospective noninterventional nonrandomized clinical study protocol.
biliary tract cancer
copper
predictive biomarkers of response
systemic treatment
trace elements
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
30 Mar 2024
30 Mar 2024
Historique:
received:
18
02
2024
accepted:
09
03
2024
medline:
30
3
2024
pubmed:
30
3
2024
entrez:
29
3
2024
Statut:
aheadofprint
Résumé
Biliary tract cancers (BTCs) are usually diagnosed at an advanced stage, when the disease is incurable. Currently used tumor biomarkers have limited diagnostic value for BTCs, so there is an urgent need for sensitive and specific biomarkers for their earlier diagnosis. Deregulation of the homeostasis of trace elements is involved in the carcinogenesis of different cancers, including BTCs. The objective of the study is to determine/compare the total concentrations of copper (Cu), zinc (Zn) and iron (Fe) and the proportions of free Cu and Cu bound to ceruloplasmin (Cp) and the isotopic ratio of In this prospective, noninterventional, nonrandomized study 20 patients and 20 healthy volunteers will be enrolled to identify serum Cu, Zn and Fe levels, Cu isotopic fractionation as a predictive biomarker of response to systemic therapy of BTCs, which will be evaluated by computed tomography. Newly developed analytical methods based on ICP-MS will be applied to metal-based biomarker research in oncology. In the study the comparison of the total concentration of selected trace elements, the proportion of free Cu and Cu bound to Cp and the isotopic ratio of
Sections du résumé
BACKGROUND
BACKGROUND
Biliary tract cancers (BTCs) are usually diagnosed at an advanced stage, when the disease is incurable. Currently used tumor biomarkers have limited diagnostic value for BTCs, so there is an urgent need for sensitive and specific biomarkers for their earlier diagnosis. Deregulation of the homeostasis of trace elements is involved in the carcinogenesis of different cancers, including BTCs. The objective of the study is to determine/compare the total concentrations of copper (Cu), zinc (Zn) and iron (Fe) and the proportions of free Cu and Cu bound to ceruloplasmin (Cp) and the isotopic ratio of
PATIENTS AND METHODS
METHODS
In this prospective, noninterventional, nonrandomized study 20 patients and 20 healthy volunteers will be enrolled to identify serum Cu, Zn and Fe levels, Cu isotopic fractionation as a predictive biomarker of response to systemic therapy of BTCs, which will be evaluated by computed tomography. Newly developed analytical methods based on ICP-MS will be applied to metal-based biomarker research in oncology.
CONCLUSIONS
CONCLUSIONS
In the study the comparison of the total concentration of selected trace elements, the proportion of free Cu and Cu bound to Cp and the isotopic ratio of
Identifiants
pubmed: 38553250
pii: raon-2024-0026
doi: 10.2478/raon-2024-0026
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Martina Rebersek et al., published by Sciendo.
Références
Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 2019; 71: 104–14. doi: 10.1016/j.jhep.2019.03.013
doi: 10.1016/j.jhep.2019.03.013
Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet 2021; 397: 428–44. doi: 10.1016/S0140-6736(21)00153-7
doi: 10.1016/S0140-6736(21)00153-7
Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D, et al; ESMO Guidelines Committee. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 127–40. doi: 10.1016/j.annonc.2022.10.506
doi: 10.1016/j.annonc.2022.10.506
National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Biliary tract cancers. V 3. [online]. 2023. [cited 2024 Feb 18]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf
Cancer in Slovenia 2020 . Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry; 2023.
Đokic M, Stupan U, Licen S, Trotovsek B. Residual disease in lymph nodes has no influence on survival in patients with incidental gallbladder cancer − institution experience with literature review. Radiol Oncol 2021; 56: 208–15. doi: 10.2478/raon-2021-0048
doi: 10.2478/raon-2021-0048
Fostea RM, Fontana E, Torga G, Arkenau HT. Recent progress in the systemic treatment of advanced/metastatic cholangiocarcinoma. Cancers 2020; 12: 2599. doi: 10.3390/cancers12092599
doi: 10.3390/cancers12092599
Mirallas O, López-Valbuena D, García-Illescas D, Fabregat-Franco C, Verdaguer H, Tabernero, et al. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer. ESMO Open 2022; 7: 100503. doi: 10.1016/j.esmoop.2022.100503
doi: 10.1016/j.esmoop.2022.100503
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273–81. doi: 10.1056/NEJMoa0908721
doi: 10.1056/NEJMoa0908721
Oh DY, He AR, Qin S, Chen T, Okusaka T, Arndt Vogel, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1: EVID 0a2200015. doi: 10.1056/EVIDoa2200015
doi: 10.1056/EVIDoa2200015
Ferreira CR, Gahl WA. Disorders of metal metabolism. Transl Sci Rare Dis 2017; 2 : 101–39. doi: 10.3233/TRD-170015
doi: 10.3233/TRD-170015
Morales M, Xue X. Targeting iron metabolism in cancer therapy. Theranostics 2021; 11: 8412–29. doi: 10.7150/thno.59092
doi: 10.7150/thno.59092
Stojsavljević, A, Vujotić L, Rovčanin B, Borković-Mitić S, Gavrović-Jankulović, Manojlović D. Assessment of trace metal alterations in the blood, cerebrospinal fluid and tissue samples of patients with malignant brain tumors. Sci Rep 2020; 10: 3816. doi: 10.1038/s41598-020-60774-0
doi: 10.1038/s41598-020-60774-0
Lelièvre P, Sancey L, Coll JL, Deniaud A, Busser B. The multifaceted roles of copper in cancer: A trace metal element with dysregulated metabolism, but also a target or a bullet for therapy. Cancers 2020; 12: 3594. doi: 10.3390/cancers12123594
doi: 10.3390/cancers12123594
Chen F, Han B, Meng Y, Han Y, Liu B, Zhang B, et al. Ceruloplasmin correlates with immune infiltration and serves as a prognostic biomarker in breast cancer. Aging 2021; 13: 20438–67. doi: 10.18632/aging.203427
doi: 10.18632/aging.203427
Wang B, Wang XP. Does ceruloplasmin defend against neurodegenerative diseases? Curr Neuropharmacol 2019; 17: 539–49. doi: 10.2174/1570159X16666180508113025
doi: 10.2174/1570159X16666180508113025
Linder MC. Ceruloplasmin and other copper binding components of blood plasma and their functions: an update. Metallomics 2016; 8: 887–905. doi: 10.1039/c6mt00103c
doi: 10.1039/c6mt00103c
Mukae Y, Ito H, Miyata Y, Araki K, Matsuda T, Aibara N, et al. Ceruloplasmin levels in cancer tissues and urine are significant biomarkers of pathological features and outcome in bladder cancer. Anticancer Res 2021; 41: 3815–23. doi: 10.21873/anticanres.15174
doi: 10.21873/anticanres.15174
Sogabe M, Kojima S, Kaya T, Tomioka A, Kaji H, Sato T, et al. Sensitive new assay system for serum wisteria floribunda agglutinin-reactive ceruloplasmin that distinguishes ovarian clear cell carcinoma from endometrioma. Anal Chem 2022; 94: 2476–84. doi: 10.1021/acs.analchem.1c04302
doi: 10.1021/acs.analchem.1c04302
Michalczyk K, Cymbaluk-Płoska A. The role of zinc and copper in gynecological malignancies. Nutrients 2020; 12: 3732. doi: 10.3390/nu12123732
doi: 10.3390/nu12123732
Woimant F, Djebrani-Oussedik N, Poujois A. New tools for Wilson’s disease diagnosis: exchangeablecopper fractio. Ann Transl Med 2019; 7(Suppl 2): S70. doi: 10.21037/atm.2019
doi: 10.21037/atm.2019
WHO Guidelines Review Committee, Nutrition and Food Safety (NFS). WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations [Internet]. Geneva: World Health Organization 2020. [cited 2024 Jan 15]. Available at: https://www.who.int/publications/i/item/9789240000124 . PMID: 33909381
pubmed: 33909381
Lossow K, Schwarz M, Kipp AP. Are trace element concentrations suitable biomarkers for the diagnosis of cancer? Redox Biol 2021; 42: 101900. doi: 10.1016/j.redox.2021.101900
doi: 10.1016/j.redox.2021.101900
Chen F, Han B, Meng Y, Han Y, Liu B, Zhang B, et al. Ceruloplasmin correlates with immune infiltration and serves as a prognostic biomarker in breast cancer. Aging 2021; 13: 20438–67. doi: 10.18632/aging.203427
doi: 10.18632/aging.203427
Balter V, Nogueira da Costa A, Bondanese VP, Jaouen K, Lamboux A, et al. Natural variations of copper and sulfur stable isotopes in blood of hepatocellular carcinoma patients. Proc Natl Acad Sci U S A 2015; 112: 982–5. doi: 10.1073/pnas.1415151112
doi: 10.1073/pnas.1415151112
Hastuti AAMB, Costas-Rodríguez M, Matsunaga A, Ichinose T, Hagiwara S, Shimura M, et al. Cu and Zn isotope ratio variations in plasma for survival prediction in hematological malignancy cases. Sci Rep 2020; 10: 16389. doi: 10.1038/s41598-020-71764-7
doi: 10.1038/s41598-020-71764-7
Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, et al. Connecting copper and cancer: from transition metal signaling to metalloplasia. Nat Rev Cancer 2022; 22: 102–13. doi: 10.1038/s41568-021-00417-2
doi: 10.1038/s41568-021-00417-2
Wang J, Zhao H, Xu Z, Cheng X. Zinc dysregulation in cancers and its potential as a therapeutic target. Cancer Biol Med 2020; 17: 612–25. doi: 10.20892/j.issn.2095-3941.2020.0106
doi: 10.20892/j.issn.2095-3941.2020.0106
Krężel A, Maret W. The biological inorganic chemistry of zinc ions. Arch Biochem Biophys 2016; 611: 3–19. doi: 10.1016/j.abb.2016.04.010
doi: 10.1016/j.abb.2016.04.010
Infusino I, Valente C, Dolci A, Panteghini M. Standardization of ceruloplasmin measurements is still an issue despite the availability of a common reference material. Anal Bioanal Chem 2009; 397: 521–5. doi: 10.1007/s00216-009-3248-0
doi: 10.1007/s00216-009-3248-0
Quarles CD, Macke M Jr, Michalke B, Zischka H, Karst U, Sullivan P, et al. LC-ICP-MS method for the determination of “extractable copper” in serum. Metallomics 2020; 12: 1348–55. doi: 10.1039/d0mt00132e
doi: 10.1039/d0mt00132e
Neselioglu S, Ergin M, Erel O. A new kinetic, automated assay to determine the ferroxidase activity of ceruloplasmin. Anal Sci 2017; 33: 1339–44. doi: 10.2116/analsci.33.1339
doi: 10.2116/analsci.33.1339
Solovyev N, Ala A, Schilsky M, Mills C, Willis, K, Harrington C F. Biomedical copper speciation in relation to Wilson’s disease using strong anion exchange chromatography coupled to triple quadrupole inductively coupled plasma-mass spectrometry. Anal. Chim Acta 2020; 1098: 27–36. doi: 10.1016/j.aca.2019.11.033
doi: 10.1016/j.aca.2019.11.033
Bernevic B, El-Khatib AH, Jakubowski N, Weller MG. Online immunocapture ICP-MS for the determination of the metalloprotein ceruloplasmin in human serum. BMC Res Notes 2018; 11: doi: 10.1186/s13104-018-3324-7
doi: 10.1186/s13104-018-3324-7
Marković K, Milačič R, Vidmar J, Marković S, Uršič K, Nikšić Žakelj M, et al. Monolithic chromatography on conjoint liquid chromatography columns for speciation of platinum-based chemotherapeutics in serum of cancer patients. J Trace Elem Med Biol 2020; 57: 28–39. doi: 10.1016/j.jtemb.2019.09.011
doi: 10.1016/j.jtemb.2019.09.011
Marković K, Milačič R, Marković S, Kladnik J, Turel I, Ščančar J. Binding kinetics of ruthenium pyrithione chemotherapeutic candidates to human serum proteins studied by HPLC-ICP-MS. Molecules 2020; 25: 1512–3. doi: cules25071512
Martinčič A, Čemažar M, Serša G, Kovač V, Milačič R, Ščančar J. A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection. Talanta 2013; 116: 141–8, doi: 10.1016/j.talanta.2013.05.016
doi: 10.1016/j.talanta.2013.05.016
Martinčič A, Milačič R, Vidmar J, Turel I, Keppler BK, Ščančar J. New method for the speciation of Ru-based chemotherapeutics in human serum by conjoint liquid chromatography on affinity and anion-exchange monolithic disks. J Chromatogr A 2014; 1371: 168–76. doi: 10.1016/j.chroma.2014.10.054
doi: 10.1016/j.chroma.2014.10.054
Marković K, Cemazar M, Sersa G, Milačič R, Ščančar J. Speciation of copper in human serum using conjoint liquid chromatography on short-bed monolithic disks with UV and post column ID-ICP-MS detection. J Anal At Spectrom 2022; 37: 1675–86. doi: 10.1039/D2JA00161F
doi: 10.1039/D2JA00161F
Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 2016; 62: 132–7. doi: 10.1016/j.ejca.2016.03.081
doi: 10.1016/j.ejca.2016.03.081
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143–e52. doi: 10.1016/S1470-2045(17)30074-8 . Erratum in: Lancet Oncol 2019; 20: e242.
doi: 10.1016/S1470-2045(17)30074-8
National Cancer Institute (NCI). NCI common terminology criteria for adverse events (CTCAE). Version 5.0.2021. [cited 2024 Feb 18]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf